Liver cancer combo trial pulled before starting
NCT ID NCT06608940
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 29 times
Summary
This study aimed to test a new experimental drug called BC3402 combined with two other drugs (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal was to see if the combination was safe and effective. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.